DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0112135 A1 Cormier Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0112135 A1 Cormier Et Al US 2005O112135A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0112135 A1 Cormier et al. (43) Pub. Date: May 26, 2005 (54) ULTRASOUND ASSISTED TRANSIDERMAL Publication Classification WACCINE DELIVERY METHOD AND SYSTEM (51) Int. Cl." .......................... A61K 39/12; A61M 31/00 (52) U.S. Cl. ......................................... 424/185.1; 604/500 (76) Inventors: Michel J.N. Cormier, Mountain View, CA (US); WeiOi Lin, Palo Alto, CA (US); Georg Widera, Palo Alto, CA (57) ABSTRACT (US) An apparatus and method for transdermally delivering a vaccine comprising a delivery System having (i) a micro Correspondence Address: projection member (or System) that includes a plurality of Francis Law Group microprojections (or array thereof) that are adapted to pierce 1942 Embarcadero through the Stratum corneum into the underlying epidermis Oakland, CA 94.606 (US) layer, or epidermis and dermis layers and (ii) an ultrasonic device. In one embodiment, the vaccine is contained in a (21) Appl. No.: 10/971,338 biocompatible coating that is applied to the microprojection Filed: Oct. 21, 2004 member. In a further embodiment, the delivery system (22) includes a gel pack having a vaccine-containing hydrogel Related U.S. Application Data formulation that is disposed on the microprojection member after application to the skin of a patient. In an alternative (60) Provisional application No. 60/524,062, filed on Nov. embodiment, the vaccine is contained in both the coating 21, 2003. and the hydrogel formulation. Patent Application Publication May 26, 2005 Sheet 1 of 5 US 2005/0112135 A1 W EL ( (( Patent Application Publication May 26, 2005 Sheet 2 of 5 US 2005/0112135 A1 Patent Application Publication May 26, 2005 Sheet 3 of 5 US 2005/0112135 A1 40 7777.2/ZZZZZZZZYZZZZZZZYZZZYZZ 22222222222222222 36 34 34- 30 7 Will,% 50 larAn inIL FIG, 5 Patent Application Publication May 26, 2005 Sheet 4 of 5 US 2005/0112135 A1 Patent Application Publication May 26, 2005 Sheet 5 of 5 US 2005/0112135 A1 US 2005/0112135 A1 May 26, 2005 ULTRASOUND ASSISTED TRANSIDERMAL trafficking to regional skin-draining lymph nodes, and pre WACCINE DELIVERY METHOD AND SYSTEM Senting processed antigens to T cells. CROSS-REFERNCE TO RELATED 0008. The effectiveness of the skin immune system is APPLICATIONS responsible for the Success and Safety of vaccination Strat egies that have been targeted to the skin. Vaccination with a 0001) This application claims the benefit of U.S. Provi live-attenuated Smallpox vaccine by Skin Scarification has sional Application No. 60/524,062, filed Nov. 21, 2003. Successfully led to global eradication of the deadly Small poX disease. Intradermal injection using /S to /10 of the FIELD OF THE PRESENT INVENTION standard IM doses of various vaccines has been effective in 0002 The present invention relates generally to transder inducing immune responses with a number of vaccines mal vaccine delivery Systems and methods. More particu while a low-dose rabies vaccine has been commercially larly, the invention relates to an ultrasound assisted vaccine licensed for intradermal application. delivery method and System 0009 Transdermal delivery offers significant advantages for vaccination, given the function of the skin as an immune BACKGROUND OF THE INVENTION organ. Pathogens entering the Skin are confronted with a 0003) Active agents (or drugs) are most conventionally highly organized and diverse population of Specialized cells administered either orally or by injection. Unfortunately, capable of eliminating microorganisms through a variety of many active agents are completely ineffective or have radi mechanisms. Epidermal Langerhans cells are potent anti cally reduced efficacy when orally administered, Since they gen-presenting cells. Lymphocytes and dermal macrophages either are not absorbed or are adversely affected before percolate throughout the dermis. Keratinocytes and Langer entering the bloodstream and thus do not possess the desired hans cells express or can be induced to generate a diverse activity. On the other hand, the direct injection of an agent array of immunologically active compounds. Collectively, into the bloodstream, while assuring no modification of the these cells orchestrate a complex Series of events that agent during administration, is a difficult, inconvenient, ultimately control both innate and Specific immune painful and uncomfortable procedure which Sometimes responses. results in poor patient compliance. 0010. It is further thought that non-replicating antigens 0004 Hence, in principle, transdermal delivery provides (i.e., killed viruses, bacteria, an Subunit vaccines) enter the for a method of administering active agents that would endoSomal pathway of antigen presenting cells. The anti otherwise need to be administered orally, by hypodermic gens are processed and expressed on the cell Surface in injection or by intravenous infusion. Transdermal delivery, association with class II MHC molecules, leading to the when compared to oral delivery, avoids the harsh environ activation of CD4 T cells. Experimental evidence indicates ment of the digestive tract, bypasses gastrointestinal drug that introduction of antigens exogenously induces little or no metabolism, reduces first-pass effects, and avoids the poS cell Surface antigen expression associated with class I MHC, Sible deactivation by digestive and liver enzymes. resulting in ineffective CD8" Tactivation. Replicating vac cines, on the other hand (e.g., live, attenuated viruses, Such 0005 The word “transdermal”, as used herein, is generic as polio and Smallpox vaccines) lead to effective humoral term that refers to delivery of an active agent (e.g., a and cellular immune responses and are considered the "gold therapeutic agent, Such as a drug or an immunologically Standard” among vaccines. A similar broad immune active agent, Such as a vaccine) through the skin to the local response Spectrum can be achieved by DNA vaccines. tissue or Systemic circulatory System without Substantial cutting or penetration of the skin, Such as cutting with a 0011. In contrast, polypeptide based vaccines, like Sub Surgical knife or piercing the skin with a hypodermic needle. unit vaccines, and killed Viral and bacterial vaccines do elicit Transdermal agent delivery includes delivery via passive predominantly a humoral response, as the original antigen diffusion as well as delivery based upon external energy presentation occurs via the class II MHC pathway. A method Sources, Such as electricity (e.g., iontophoresis) and ultra to enable the presentation of these vaccines also via the class Sound (e.g., phonophoresis). I MHC pathway would be of great value, as it would widen the immune response spectrum. 0006 AS is well known in the art, skin is not only a physical barrier that shields the body from external hazards, 0012 Several reports have suggested that soluble protein but is also an integral part of the immune System. The antigens can be formulated with Surfactants, leading to immune function of the skin arises from a collection of antigen presentation via the class I pathway and induce residential cellular and humoral constituents of the viable antigen-specific class I-restricted CTLS (Raychaudhuri, et epidermis and dermis with both innate and acquired immune al., 1992). Introduction of protein antigen by osmotic lysis functions, collectively known as the skin immune System. of pinosomes has also been demonstrated to lead to a class I antigen-processing pathway (Moore, et al.). Ultrasound 0007 One of the most important components of the skin techniques have been used to introduce macromolecules into immune System are the Langerhan's cells (LC), which are cells in vitro and in vivo, and, particularly, DNA-based Specialized antigen presenting cells found in the viable therapeutics. Studies with plasmid DNA have clearly dem epidermis. LCS form a Semi-continuous network in the viable epidermis due to the extensive branching of their onstrated that the delivery efficiency can be significantly dendrites between the Surrounding cells. The normal func enhanced when ultrasound is employed. tion of the LCS is to detect, capture and present antigens to 0013 There is, however, no published literature regard evoke an immune response to invading pathogens. LCS ing in Vivo intracellular ultrasound delivery of protein-based perform his function by internalizing epicutaneous antigens, vaccines into skin antigen-presenting cells (APC) that leads US 2005/0112135 A1 May 26, 2005 to cellular loading of the protein onto class I MHC/HLA outermost layer (i.e., the Stratum corneum) of the skin. The presentation molecules in addition to class II MHC/HLA piercing elements disclosed in these references generally presentation molecules. In particular, there is no mention of extend perpendicularly from a thin, flat member, Such as a the use of a microprojection array in conjunction with pad or sheet. The piercing elements in Some of these devices ultrasound to achieve this means. are extremely Small, Some having a microprojection length 0.014. There is also no published literature mentioning the of only about 25-400 microns and a microprojection thick use of a microprojection array in conjunction with ultra neSS of only about 5-50 microns. These tiny piercing/cutting sound to achieve in vivo delivery of a DNA vaccine intra elements make correspondingly Small microSlits/microcuts cellularly and Subsequent cellular expression and loading of in the Stratum corneum for enhancing transdermal
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • L IIDIII11H11 IIHI DID IIDI1IIII11 ID1 I Hill1hib IIHI DIII DII DID I1 IIIIIH
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau l IIDIII11H11IIHI DIDIIDI1IIII11 ID1IHill1HIB IIHI DIII DII DIDI1 IIIIIH I11111IIII (43) International Publication Date (10) International Publication Number 3 November 2005 (03.11.2005) W O 2005/102334 A3 (51) International Patent Classification : A61K 9170 At AU. AZ, HA, BB, HG, BR, BW, BY, HZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, FE, EU, ES, HI, (21) International Application Number: GB, GD, GE, OH, GM, HR, HU, ID, IL, IN, IS, J, KU, PCT/US2005/009153 KG, Kg KR, KZ, LC, LK, LR, LS, T LU, LV, MA, MD, (22) International Filing Date: 18 March 2005 (18.03.2005) P, PL, PT, RO, U, D, SE, SO, SK, NL, SM, SG, TJ, TM, T, R, IT, TZ, UA, UG, US, UZ, SC, VN, Y, (25) Filing Language: English T, ZM, TU (26) Publication Language: English (84) Designated States (unless otherwise indicated, fi6r every (30) Priority Data: kind of regional protection available): ARIPO (BW OH, 60/561,949 13 April 2004 (13.04.2004) US GM, KE, LS. MW, MZ, NA, SD. SL, SZ. IL, UG, ZM, LW), Eurasian (AM, AL, BY, KG, KZ, MD, RU, Ti,TM), (71) Applicant (for all designated States except US): ALZA European (AT, BE, BO, CH, CY, CZ, DE, DK, EE, ES, H, CORPORATION [US/US]; 1900 Charleston Road, P.O. ER, GB, OR, ItO, TE, IS, IT, LI, LU, MC, NE, PL, PT, RO, Box 7210, Mountain View, CA 94043 (US). SE, 81,5K,'R), QAPI (HF BJ, CE, CG, CI, CM, GA, ON, (72) Inventors; and GQ, OW, ML, MR, NE, SN, ID, TO).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]